Among the best clinically documented are two therapies: DC/AML fusion vaccines, an autologous fusion of DC with leukemic cells, demonstrating safety, the ability to activate CD8+ T cells, and control MRD [194], and the other is DCP-001, an allogeneic AML-derived product, an “off-the-shelf” vaccine that combines safety with a broad antigenic profile [195,196,197]. The gene discussed is CD8A; the disease is acute myeloid leukemia.